The awards were presented on Thursday 9 September
News
UK terminates Valneva COVID-19 vaccine supply agreement
Gov has alleged that the company breached its obligations under the agreement
NHS England launches large-scale trial of ‘revolutionary’ cancer test
The Galleri test is able to identify the ‘earliest’ signs of cancer in the blood
NICE OKs Xeljanz for individuals with juvenile idiopathic arthritis
Xeljanz is the second drug to be recommended as part of NICE’s new approach to the cost comparison fast track appraisal process
Entry deadline extended for the 2021 Marketer of the Year, Sales and Communications Awards!
The entry deadline for the 2021 Marketer of the Year, Sales and Communications Awards has been extended to 22nd of October
MHRA approves Amgen’s Lumykras under Project Orbis
Project Orbis is an international collaborative programme between the FDA and worldwide regulatory agencies
UK approval for Pfizer’s JAK inhibitor Cibinqo
Treatment approved for adults and adolescents with moderate to severe atopic dermatitis
Sanofi’s oral BTK inhibitor rilzabrutinib fails Phase III trial
Rilzabrutinib missed primary and secondary endpoints as a treatment for pemphigus
AZ builds case for fixed-dose albuterol and budesonide combo in asthma
Positive results revealed from two Phase III trials of potential asthma therapy
Novavax begins COVID-19, flu combination vaccine trial
The trial will aim to enrol 640 healthy adults, aged 50- to 70-years-old
Gov’t consultation to consider mandatory COVID-19 vaccination for health staff
Consultation will also ask for views on whether flu vaccines should be a requirement for health and care staff
Positive interim data for Ixaka’s lead ‘multi-cell’ therapy
The independent data monitoring committee (DMC) has recommended continuation of the Phase III trial
NICE changes its mind on Janssen’s Erleada
Prostate cancer therapy now recommended for two indications within its marketing authorisation
Sanofi adds to transplant portfolio with Kadmon buy
Sanofi will acquire Kadmon for $9.50 per share in cash, representing a total equity value of around $1.9bn
Gov’t injects £5.4bn to support NHS England’s COVID-19 response
Funds will be used over the next six months to tackle waiting lists and manage ‘immediate pressures’
